Rhythm Pharmaceuticals Gains as Obesity Drug Leaders Eli Lilly, Novo Nordisk Slip
1h ago|5 min readStandard
Fazen Markets Editorial Desk
Collective editorial team · methodology
obesity-drugsbiotech
Fazen Markets Editorial Desk
Collective editorial team · methodology
Trades XAUUSD on autopilot. Verified Myfxbook performance. Free forever.
Risk warning: CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. The majority of retail investor accounts lose money when trading CFDs. AiX is informational software — not investment advice. Past performance does not guarantee future results.
Eli Lilly traded lower on Friday, with its shares falling 1.95% to $1,255.40 as of 22:41 UTC today. The decline occurred alongside market attention on Rhythm Pharmaceuticals, following reports that billionaire investor Stanley Druckenmiller is betting on the smaller firm's approach to treating rare genetic forms of obesity. This price action highlights a divergence within the obesity therapeutics sector, where established leaders face competition from firms targeting specific patient populations. Lilly's shares traded within a daily range of $1,230 to $1,271.22 during the session.
The obesity drug market, dominated by Eli Lilly's tirzepatide and Novo Nordisk's semaglutide, represents one of the most valuable therapeutic classes in modern medicine. Global sales for GLP-1 agonists are projected to exceed $100 billion annually by the end of the decade. These blockbuster drugs primarily address common obesity related to metabolic syndrome and lifestyle factors.
Their mechanism of action, however, is ineffective for monogenic obesity disorders caused by specific genetic mutations. Conditions like Bardet-Biedl syndrome and Prader-Willi syndrome originate from defects in the melanocortin-4 receptor pathway, a different biological system than the one targeted by GLP-1 drugs. This therapeutic gap creates a niche market for highly specialized treatments.
The current macro backdrop for biotech investing remains challenging, with the XBI Biotech ETF still down significantly from its 2021 highs. High interest rates have pressured valuations for pre-profitability companies, making investor validation from figures like Druckenmiller particularly impactful. His track record of identifying emerging thematic shifts lends credibility to bets on novel treatment paradigms.
Eli Lilly's intraday decline of 1.95% represents a notable move for a mega-cap stock with a market valuation exceeding $600 billion. The stock price of $1,255.40 sits near the lower end of its daily trading range between $1,230 and $1,271.22, indicating selling pressure throughout the session. This performance contrasts with the broader healthcare sector, which was roughly flat on the day.
Rhythm Pharmaceuticals, while not in the live data feed, has a market capitalization of approximately $2 billion, dwarfed by Lilly's scale. The company's lead drug, Imcivree (setmelanotide), is approved for use in specific genetic obesity disorders. Treatment costs for these rare conditions can exceed $100,000 annually, creating a high-value per-patient business model despite the small patient population.
The market for monogenic obesity disorders is measured in thousands of patients globally, compared to the hundreds of millions who qualify for GLP-1 therapies. This specialization means Rhythm's commercial opportunity is a fraction of Lilly's, but its targeted approach offers potentially superior efficacy for its specific indications. Analyst price targets for Rhythm have varied widely, reflecting the uncertainty around diagnosis rates and market penetration for ultra-orphan drugs.
| Metric | Eli Lilly | Niche Biotech (e.g., RYTM) |
|---|---|---|
| Market Focus | Broad metabolic obesity | Rare genetic obesity disorders |
| Target Patient Population | ~100 million+ US adults | ~5,000-10,000 US patients |
| Annual Treatment Cost | ~$10,000-$15,000 | ~$100,000+ |
The investment thesis for Rhythm Pharmaceuticals rests on market expansion through improved genetic testing and diagnosis rather than competition with Lilly or Novo. As genetic sequencing becomes more commonplace, identification of patients with MC4 pathway deficiencies is expected to increase. This could expand the addressable market for setmelanotide beyond current estimates.
The main counter-argument concerns the scalability of ultra-orphan drug commercializations. Diagnosing rare genetic disorders requires significant physician education and diagnostic infrastructure, which typically slows revenue growth compared to mass-market drugs. Reimbursement challenges from payers scrutinizing six-figure annual treatments present another commercial headwind.
Second-order effects could benefit companies in the genetic testing space, such as Invitae or Quest Diagnostics, as increased focus on genetic obesity drivers might spur more diagnostic referrals. Contract research organizations that manage clinical trials for rare diseases, like ICON plc or PPD, could also see increased demand as more biotechs pursue targeted therapies.
Positioning data suggests specialist healthcare hedge funds have been accumulating positions in targeted therapy companies while some generalist funds have trimmed GLP-1 holdings on valuation concerns. Flow has been moving toward highly specific biological mechanisms with clear genetic validation, a trend that extends beyond obesity into oncology and neurology.
The next major catalyst for the genetic obesity space will be Rhythm Pharmaceuticals' Q3 earnings report in early November, where management will likely update prescription growth for Imcivree. Investors will scrutinize prescription trends and any commentary on diagnostic rates.
Key levels to watch for Eli Lilly include the $1,230 support level, which held during today's session. A break below that level could signal further near-term weakness toward its 50-day moving average, currently around $1,190. For Rhythm, investors will watch whether it can maintain momentum above its key technical resistance levels.
The American Society of Human Genetics annual meeting in October may feature new clinical data on genetic obesity disorders, potentially moving stocks in the sector. The FDA's decision timeline for Rhythm's supplemental New Drug Application for additional indications remains another pending catalyst, expected by year-end.
Monogenic obesity disorders are rare conditions caused by a mutation in a single gene that severely disrupts the body's appetite regulation system. The most common involve the melanocortin-4 receptor pathway, which controls hunger signals and energy expenditure. Unlike typical obesity, these conditions often manifest in early childhood with extreme, insatiable hunger and rapid weight gain that doesn't respond to diet or conventional medications. Diagnosis requires specific genetic testing that isn't routinely performed.
Setmelanotide works as a melanocortin-4 receptor agonist that directly activates the defective pathway in genetic obesity disorders. GLP-1 drugs like those from Lilly and Novo work by mimicking gut hormones that slow gastric emptying and stimulate insulin secretion. They operate on different biological systems—setmelanotide addresses a specific genetic defect, while GLP-1s enhance existing metabolic pathways. This fundamental difference means patients with MC4 pathway mutations typically don't respond to GLP-1 therapy.
The primary investment risk concerns market size limitations and diagnostic challenges. These therapies treat extremely rare conditions that require specialized genetic testing for identification, creating a commercial ramp that depends on physician education and testing adoption. Reimbursement presents another significant risk, as insurers may resist covering expensive therapies without strong real-world outcomes data. Companies also face regulatory risk if expansion into broader indications doesn't demonstrate sufficient efficacy.
Market attention is shifting from broad obesity drugs to targeted therapies for niche genetic disorders.
Disclaimer: This article is for informational purposes only and does not constitute investment advice. CFD trading carries high risk of capital loss.
AiX is our free MetaTrader 4 Expert Advisor. Verified Myfxbook performance. No subscription. No fees. XAUUSD breakout engine.
Position yourself for the macro moves discussed above
Start TradingSponsored
Open a demo account in 30 seconds. No deposit required.
CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.